StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Corporate ActionJul 7, 2026, 04:33 PM

Nuwellis Seeks Shareholder Approval for Reverse Stock Split and Warrant Issuance

AI Summary

Nuwellis, Inc. announced a Special Meeting of Stockholders on July 24, 2026, to vote on key corporate actions. Shareholders will consider approving a reverse stock split at a ratio between 1-for-5 and 1-for-70 to maintain Nasdaq listing compliance. Additionally, approval is sought for the issuance of up to 2,396,709 shares upon the exercise of warrants, which could generate approximately $18.3 million in proceeds crucial for funding operations. The Board unanimously recommends approval for all proposals.

Key Highlights

  • Special Meeting of Stockholders scheduled for July 24, 2026, to vote on three proposals.
  • Proposal 1 seeks approval for the issuance of up to 2,396,709 shares from warrant exercises.
  • Proposal 2 requests approval for a reverse stock split at a ratio of 1-for-5 to 1-for-70.
  • The reverse stock split aims to comply with Nasdaq's continued listing requirements.
  • Failure to approve warrant exercises would prevent the company from receiving approximately $18.3 million in proceeds.
  • As of June 5, 2026, Nuwellis had 92,201 common shares outstanding (post 1-for-35 reverse split).
  • The Board of Directors unanimously recommends voting FOR all three proposals.